Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment;Eficácia terapêutica e segurança de metotrexato + leflunomida em pacientes colombianos com artrite reumatoide ativa refratária ao tratamento convencional

Revista Brasileira de Reumatologia

Volumn 52, Issue 6, 2012, Pages 837-845

  Londono, John ^a   Santos, Ana Maria ^b   Santos, Pedro Ivan ^a   Cubidez, Maria Fernanda ^a   Guzman, Claudia ^c   Valle Oñate, Rafael ^a  

^a UNIVERSIDAD DE LA SABANA   (Colombia)

^b UNIVERSIDAD DE LOS ANDES   (Colombia)

^c UNIVERSIDAD MILITAR NUEVA GRANADA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISOLONE; PREDNISONE;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ARTHRITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COLOMBIA; COMMON COLD; COMMUNITY ACQUIRED PNEUMONIA; DAS28; DIABETES INSIPIDUS; DIABETES MELLITUS; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; INJURY; LEUKOCYTE COUNT; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MYALGIA; OPEN STUDY; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SIDE EFFECT; TRIGGER FINGER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CHILD; COLOMBIA; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; YOUNG ADULT;

EID: 84873052050     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0482-50042012000600003     Document Type: Article

References (37)

1. Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med 1980; 93(4):551-6.
2. Lawrence R, Helmick C, Arnett F, Deyo R, Felson D, Giannini E et al. Estimates of the prevalence of arthritis and selected musculoskeletal. Arthritis Rheum 1998; 41(5):778-99.
3. Anaya JM, Correa PA, Mantilla RD, Jimenez F, Kuffner T, McNicholl JM. Rheumatoid arthritis in African Colombians from Quibdo. Semin Arthritis Rheum 2001; 31(3):191-8.
4. Spindler A, Bellomio V, Berman A, Lucero E, Baigorria M, Paz S et al. Prevalence of rheumatoid arthritis in Tucuman, Argentina. J Rheumatol 2002; 29(6):1166-70.
5. Senna ER, De Barros AL, Silva EO, Costa IF, Pereira LV, Ciconelli RM et al. Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol 2004; 31(3):594-7.
6. Cardiel MH, Rojas-Serrano J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol 2002; 20(5):617-24.
7. Cardiel MH. First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. Rheumatology (Oxford) 2006; 45(Suppl 2):ii7-ii22.
8. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334(20):1287-91.
9. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999; 93(3):198-208.
10. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159(21):2542-50.
11. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353(9149):259-66.
12. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42(7):1322-8.
13. Alves JA, Fialho SC, Morato EF, Castro GR, Zimmermann AF, Ribeiro GG et al. Liver toxicity is rare in rheumatoid arthritis patients using combination therapy with leflunomide and methotrexate. Rev Bras Reumatol 2011; 51(2):141-4.
14. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137(9):726-33.
15. Furst D, Luggen M, Thompson A, Colleman J. Adding leflunomide to patients with active rheumatoid arthritis while receiving methotrexate improves physical function and health-related quality of life Arthritis Rheum. [Abstract]. 2000; 43:S344.
16. Bertolo MB, Brenol CV, Schainberg CG, Neubarth F, Lima FACd, Laurindo IM et al. Update on the Brazilian Consensus for the Diagnosis and Treatment of Rheumatoid Arthritis. Ver Bras Reumatol 2007; 47:151-9.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31(3):315-24.
18. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38(6):727-35.
19. Lee SS, Park YW, Park JJ, Kang YM, Nam EJ, Kim SI et al. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. Scand J Rheumatol 2009; 38(1):11-4.
20. Antony T, Jose VM, Paul BJ, Thomas T. Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis. Indian J Med Sc 2006; 60(8):318-26.
21. Uribe-Caballero CV, Chalem P, Londoño J. Tratamiento de la Artritis Reumatoide en Colombia. Aplicación práctica de los conceptos teóricos por parte de los reumatólogos colombianos. Rev Colomb Reumatol 2002; 9(4):242-50.
22. Mottonen TT, Hannonen PJ, Boers M. Combination DMARD therapy including corticosteroids in early rheumatoid arthritis. Clin Exp Rheumatol 1999; 17(6 Suppl 18):S59-65.
23. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333(3):137-41.
24. Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, Caulfield JP et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995; 275(2):1043-9.
25. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39(12):1951-60.
26. Van Riel P. Leflunomide improves the clinical response in patients with active rheumatoid arthritis treated with methotrexate. Clin Exp Rheumatol 2003; 21(6):695-6.
27. Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 1999; 42(9):1870-8.
28. Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009; 32(12):1123-34.
29. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54(2):628-34.
30. Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010; 105(11):2396-404.
31. Weinblatt ME, Dixon JA, Falchuk KR. Serious liver disease in a patient receiving methotrexate and leflunomide. Arthritis Rheum 2000; 43(11):2609-11.
32. Dougados M, Emery P, Lemmel EM, de la Serna R, Zerbini CA, Brin S et al. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data. J Rheumatol 2003; 30(12):2572-9.
33. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003; 30(6):1182-90.
34. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009; 68(7):1100-4.
35. Maddison P, Kiely P, Kirkham B, Lawson T, Moots R, Proudfoot D et al. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology (Oxford) 2005; 44(3):280-6.
36. Pineda-Tamayo R, Arcila G, Restrepo P, Tobón GJ, Camargo J, Anaya JM. Costos médicos directos dela artritis reumatoide temprana. Rev Colomb Reumatol 2005; 11(2):89-96.
37. Mora C, Gonzalez A, Diaz J, Quintana G. Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia. Biomedica 2009; 29(1):43-50.